Markets:

Overview

News

Currencies

International

Treasuries

Vertex Pharmaceuticals (NQ:VRTX)

454.49 +1.13 (+0.25%)

Streaming Delayed Price Updated: 10:21 AM EST, Jan 2, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Vertex Pharmaceuticals

< Previous 1 2 3 4 5 6 7 8 9

...

69 70 Next >

3 Top Stocks to Buy in December ↗

December 01, 2025

These stocks deserve a spot on investors' shopping lists this holiday season.

Via The Motley Fool

Meet the Beaten-Down Biotech Stock Cathie Wood Loves That Wall Street Says May Soar 50% ↗

November 30, 2025

This company's first product has started to generate revenue.

Via The Motley Fool

Topics ETFs

Vertex (VRTX) Q3 2025 Earnings Call Transcript ↗

November 27, 2025

Vertex (VRTX) Q3 2025 Earnings Call Transcript

Via The Motley Fool

Topics Earnings

Where Will Vertex Pharmaceuticals Be in 5 Years ↗

November 27, 2025

Prediction: Vertex will be much larger by the end of the decade.

Via The Motley Fool

2 Healthcare Stocks For Beginner Investors With a 30-Year Time Horizon ↗

November 23, 2025

If you're investing for the next 30 years, don't overlook these top stocks.

Via The Motley Fool

Topics Intellectual Property

Vertex Pharmaceuticals (VRTX) Stock Trades Up, Here Is Why

November 21, 2025

Shares of biotech company Vertex Pharmaceuticals (NASDAQ:VRTX) jumped 2.7% in the afternoon session after comments from a key Federal Reserve official bolstered hopes for an interest rate cut.

Via StockStory

Topics Artificial Intelligence Economy Supply Chain

2 Inflation-Proof Growth Stocks That Could Outperform the Market ↗

November 20, 2025

Inflation should have a minimal impact on these companies' financial results. And they also boast excellent growth prospects.

Via The Motley Fool

Topics Economy Intellectual Property

Vertex Pharmaceuticals Inc (NASDAQ:VRTX) Presents a Compelling Case for Value Investors ↗

November 20, 2025

Vertex Pharmaceuticals (VRTX) presents a strong value investment case with a low P/E ratio, robust profitability, a healthy debt-free balance sheet, and accelerating earnings growth.

Via Chartmill

Agios Pharmaceuticals Plunges Over 50% as Sickle Cell Drug Delivers Mixed Phase 3 Results

November 19, 2025

Boston, MA – November 19, 2025 – Agios Pharmaceuticals, Inc. (NASDAQ: AGIO) experienced a dramatic and immediate market backlash, with its stock plummeting over 51.00% following the announcement of...

Via MarketMinute

Vertex to Participate in the Citi’s 2025 Global Healthcare Conference on December 3

November 19, 2025

From Vertex Pharmaceuticals Incorporated

Via Business Wire

Here's How Much $100 Invested In Vertex Pharmaceuticals 15 Years Ago Would Be Worth Today ↗

November 19, 2025

Via Benzinga

1 Cash-Heavy Stock with Solid Fundamentals and 2 We Ignore

November 19, 2025

Companies with more cash than debt can be financially resilient, but that doesn’t mean they’re all strong investments. Some lack leverage because they struggle to grow or generate consistent profits,...

Via StockStory

Missed Out on Eli Lilly? 2 Healthcare Stocks With Big Catalysts on the Horizon. ↗

November 19, 2025

These stocks both have advanced in the double-digits in recent months.

Via The Motley Fool

Is Vertex Pharmaceuticals Inc Gaining or Losing Market Support? ↗

November 17, 2025

Via Benzinga

1 Incredible Reason to Buy Vertex Pharmaceuticals Stock in November ↗

November 17, 2025

It's a good idea to go against the current market sentiment on this one.

Via The Motley Fool

The Tech Tsunami: How Breakthroughs in AI, Quantum, and Green Energy Are Reshaping the Stock Market

November 14, 2025

The global financial markets are in the midst of a profound transformation, driven by an accelerating wave of technological advancements. From the intricate algorithms of Artificial Intelligence to the...

Via MarketMinute

Topics Artificial Intelligence ETFs Economy

10 Health Care Stocks With Whale Alerts In Today's Session ↗

November 14, 2025

Via Benzinga

1 Safe-and-Steady Stock with Competitive Advantages and 2 We Brush Off

November 12, 2025

Stability is great, but low-volatility stocks may struggle to deliver market-beating returns over time as they sometimes underperform during bull markets.

Via StockStory

Vertex Pharmaceuticals Inc (NASDAQ:VRTX) Emerges as a Top Affordable Growth Stock ↗

November 12, 2025

Vertex Pharmaceuticals offers strong growth, solid profits, and a healthy balance sheet, all at a reasonable valuation compared to its biotech peers.

Via Chartmill

Healthcare Sector Navigates Turbulent Waters: Innovation Surges Amidst Political Headwinds

November 10, 2025

New York, NY – November 10, 2025 – The S&P 500 Healthcare sector presented a mixed picture today, with the broader index showing a modest uptick while significant segments, particularly health insurers...

Via MarketMinute

Topics Artificial Intelligence Economy Government

5 Insightful Analyst Questions From Vertex Pharmaceuticals’s Q3 Earnings Call

November 10, 2025

Vertex Pharmaceuticals’ third quarter was marked by steady double-digit revenue growth, yet the market responded negatively as margin compression and operational investments weighed on sentiment....

Via StockStory

Topics Earnings

Vertex Presents Updated Phase 1/2 Data From RUBY-3 Study That Continue to Demonstrate Best-in-Class Potential for Povetacicept in Adults with IgA Nephropathy and Primary Membranous Nephropathy at American Society of Nephrology Kidney Week

November 08, 2025

From Vertex Pharmaceuticals Incorporated

Via Business Wire

Biotech Sector Soars: Promising Drug Trials Ignite Investor Confidence and Spark Market Rally

November 07, 2025

The biotech sector is currently experiencing a robust rally, a significant turnaround from a period of subdued performance. This resurgence is primarily fueled by a wave of promising drug trial results...

Via MarketMinute

Topics Artificial Intelligence Intellectual Property

Global Markets Brace for Inflation's Enduring Grip: A November 2025 Outlook

November 07, 2025

As November 2025 unfolds, global financial markets find themselves in a complex and challenging environment, bracing for the enduring grip of inflation. Despite some signs of moderating headline...

Via MarketMinute

Topics Artificial Intelligence Bonds Economy

FDA Fast-Tracks 6 More Drugs - Obesity And Cancer Drugs Included ↗

November 07, 2025

FDA adds six drugs to its priority voucher program as CMS and the White House unveil measures to speed reviews and lower prescription costs.

Via Benzinga

2 Nasdaq 100 Stocks with Competitive Advantages and 1 Facing Challenges

November 05, 2025

While the Nasdaq 100 (^NDX) is filled with cutting-edge technology and consumer companies, not all are on solid footing. Some are dealing with declining demand, high costs, or regulatory pressures that...

Via StockStory

Palantir Weighs On Wall Street, Bitcoin Slumps 5%: What's Moving Markets Tuesday? ↗

November 04, 2025

Risk appetite cooled on Tuesday as investors interpreted the latest batch of corporate earnings as solid but not spectacular, offering a convenient excuse to take profits after strong year-to-date...

Via Benzinga

VRTX Q3 Deep Dive: New Product Launches and Pipeline Progress Shape Outlook

November 04, 2025

Biotech company Vertex Pharmaceuticals (NASDAQ:VRTX) met Wall Streets revenue expectations in Q3 CY2025, with sales up 11% year on year to $3.08 billion. The company’s outlook for the full year was...

Via StockStory

Vertex Pharmaceuticals (NASDAQ:VRTX) Reports Q3 In Line With Expectations

November 03, 2025

Via StockStory

Vertex Pharma Dips Despite Quarterly Beat And Slight Guidance Book ↗

November 03, 2025

Vertex stock dipped late Monday despite better-than-expected third-quarter metrics and a slight sales guidance boost.

Via Investor's Business Daily

< Previous 1 2 3 4 5 6 7 8 9

...

69 70 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.